Emerging Companies

Mark Herzog, executive director of the Virginia Biotechnology Association recently discussed the success and challenges facing the burgeoning bioscience industry in his state.

Current rules resulting from a 2003 Office of Hearings and Appeals decision have inhibited and interfered with the growth and survival of small private biotechnology companies and the development of promising technologies and products

The Maryland initiative’s 10-year plan helps build biotech access to funding

GEN's Editor-in-Chief John Sterling outlines his picks for the top ten "must attend" breakout sessions at the 2011 BIO International Convention.

 John Carroll, editor of Fierce Biotech, shares what he won't miss at the 2011 BIO International Convention.

Partnering decisions can make or break a company’s value. Pursuing the right partnership deal can ultimately increase a company’s value but conversely, the wrong decision can ultimately kill a company’ value.